Clinical Research Directory
Browse clinical research sites, groups, and studies.
A Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Sponsor: Forte Biosciences, Inc.
Summary
This is a randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of FB102 in patients with severe to very severe alopecia areata (AA).
Official title: A Randomized, Double-Blind, Placebo-Controlled, Multi-center Study to Evaluate the Safety and Efficacy of FB102 in Patients With Severe to Very Severe Alopecia Areata.
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
32
Start Date
2025-10-23
Completion Date
2027-03-10
Last Updated
2025-11-20
Healthy Volunteers
No
Conditions
Interventions
FB102
Route of administration- Intravenous (IV)
Placebo
Route of administration- Intravenous (IV)
Locations (6)
St Leonards
Saint Leonards, New South Wales (nsw), Australia
Coorparoo
Coorparoo, Queensland, Australia
South Yarra
South Yarra, Victoria, Australia
Auckland
Auckland, Auckland, New Zealand
Christchurch
Christchurch, Canterbury, New Zealand
Palmerston North
Palmerston North, Palmerston North Central, New Zealand